The upcoming earnings report for Ginkgo Bioworks Holdings, Inc. is scheduled for Monday, May 4th, with a consensus estimate EPS of -1.21115.
Today, DNA stock is priced at $7.69, showing a decrease of -1.66% from the previous close. The trading volume stands at $157,085, which is 13.09% above the average.
During the latest quarterly earnings on Wednesday, February 25th, Ginkgo Bioworks reported an EPS of -1.45608, surpassing the consensus estimate of -1.8.
The company experienced a net increase in cash of $54.36 million, ending the period with $174.23 million in cash. Notable outflows include $-63 million in free cash flow and $-47.68 million in operating cash flow.
Ginkgo Bioworks generated $33.40 million in revenue with a gross profit of $41.55 million. Operating expenses totaled $112.30 million, resulting in a net income of -$80.75 million.
Key ratios indicate challenges, with negative profit margins and returns. The price-to-earnings ratio is -1.43, reflecting the loss incurred.
The balance sheet shows total assets of $1.12 billion, with net debt standing at $249.88 million, and total liabilities at $611.11 million.
This analysis reveals a challenging financial landscape for Ginkgo Bioworks Holdings, Inc., with declining stock prices and negative earnings performance.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.